NCT07474727招募中2 期
An Phase II Study Evaluating the Safety and Efficacy of AMT-676 in Combination With 5-fluorouracil, Leucovorin, Bevacizumab (or Cetuximab) in Participants of Advanced Colorectal Cancer
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 180
- 试验地点
- 19
- 主要终点
- DLTs
研究概览
简要总结
This study is an open, multi-center, phase II study, aiming to evaluate the safety, tolerability and efficacy of AMT-676 combined with 5-fluorouracil, leucovorin, bevacizumab (or cetuximab) in participants with advanced colorectal cancer, and to assess the PK(Pharmacokinetic) characteristics and immunogenicity of AMT-676.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be willing and able to sign the ICF, and to adhere to the study visit schedule and other protocol requirements
- •Patients with pathologically confirmed, unresectable advanced colorectal adenocarcinoma
- •Patients must have at least one measurable lesion as per RECIST version 1.1
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- •Life expectancy ≥6 months
- •Patients must have adequate organ function
- •Male and female individuals with child bearing potential must agree to take effective contraceptive measures from the moment they sign the informed consent form until 6 months after the last administration of the study drug
- •WCBP(Women of Child-Bearing Potential) must have a negative serum pregnancy test within 7 days prior to first dose of the IMP
- •Male patients must agree not to donate sperm, and female patients must agree not to donate eggs, while on study treatment and for at least 3 months and 6 months, respectively, after the last dose of the IMP(Investigational Medicinal Product)
- •Availability of tumor tissue sample
排除标准
- •Prior treatment with any same target
- •Systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the IMP
- •Persistent toxicities from previous systemic anti-neoplastic treatments of Grade >1
- •Major surgery within 28 days prior to first dose of the IMP, or no recovery from side effects of such intervention, or a surgery is planned to be conducted within the expected participation period of the trial or within 4 weeks after the last administration of the drug
- •History of thromboembolic or cerebrovascular events during last 6 mouths
- •During the three months prior to the first administration of the drug, there were any life-threatening bleeding events, or grade 3 or higher gastrointestinal/venous variceal bleeding events that required blood transfusion, endoscopy, or surgical treatment. Or there were other diseases that the researchers believed posed a higher risk of bleeding or thrombosis during the study period
- •Has a history of interstitial lung disease (ILD)/pneumonitis that required steroids, or current ILD/pneumonitis, or suspected ILD/pneumonitis , or other lung disease significantly impacting lung function at baseline.
- •Any other concurrent diseases or conditions that could affect the research judgment or impede the completion of the research procedures and follow-up checks
- •Central nervous system (CNS) metastasis
- •Have a history of active or acute diverticulitis, abdominal abscess, gastrointestinal obstruction, fistula, or peritoneal cancer
- •Any evidence indicates severe or uncontrolled systemic diseases
- •Acute and/or clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV).
- •Administration of a live vaccine within 28 days prior to the administration of the first dose of the IMP
- •Patients requiring concurrent treatment of strong/moderate inhibitors or strong inducers of cytochrome P450 3A4 or 1A2 enzyme (CYP3A or CYP1A2) within 2 weeks prior to the first dose and during the study treatment
- •Known or suspected severe allergy/hypersensitivity (resulting in treatment discontinuation) to monoclonal antibodies
- •Known or suspected intolerance to the components of the IMP
- •Concurrent participation in another investigational therapeutic clinical trial
- •Pregnant or breast-feeding females
- •Investigator determined that the trial participants who were not suitable to participate in this study for other reasons
研究组 & 干预措施
AMT-676(dose level 1)+5-FU+Leucovorin+Bevacizumab or Cetuximab(if applicable)
Experimental
干预措施: AMT-676 (Drug)
AMT-676(dose level 1)+5-FU+Leucovorin+Bevacizumab or Cetuximab(if applicable)
Experimental
干预措施: 5-FU (Drug)
AMT-676(dose level 1)+5-FU+Leucovorin+Bevacizumab or Cetuximab(if applicable)
Experimental
干预措施: Leucovorin (Drug)
AMT-676(dose level 1)+5-FU+Leucovorin+Bevacizumab or Cetuximab(if applicable)
Experimental
干预措施: Bevacizumab (Drug)
AMT-676(dose level 1)+5-FU+Leucovorin+Bevacizumab or Cetuximab(if applicable)
Experimental
干预措施: Cetuximab (Drug)
AMT-676(dose level 2)+5-FU+Leucovorin+Bevacizumab or Cetuximab(if applicable)
Experimental
干预措施: AMT-676 (Drug)
AMT-676(dose level 2)+5-FU+Leucovorin+Bevacizumab or Cetuximab(if applicable)
Experimental
干预措施: 5-FU (Drug)
AMT-676(dose level 2)+5-FU+Leucovorin+Bevacizumab or Cetuximab(if applicable)
Experimental
干预措施: Leucovorin (Drug)
AMT-676(dose level 2)+5-FU+Leucovorin+Bevacizumab or Cetuximab(if applicable)
Experimental
干预措施: Bevacizumab (Drug)
AMT-676(dose level 2)+5-FU+Leucovorin+Bevacizumab or Cetuximab(if applicable)
Experimental
干预措施: Cetuximab (Drug)
oxaliplatin/irinotecan+5-FU+ leucovorin +bevacizumab (or cetuximab)
Experimental
干预措施: 5-FU (Drug)
oxaliplatin/irinotecan+5-FU+ leucovorin +bevacizumab (or cetuximab)
Experimental
干预措施: Leucovorin (Drug)
oxaliplatin/irinotecan+5-FU+ leucovorin +bevacizumab (or cetuximab)
Experimental
干预措施: Bevacizumab (Drug)
oxaliplatin/irinotecan+5-FU+ leucovorin +bevacizumab (or cetuximab)
Experimental
干预措施: Cetuximab (Drug)
oxaliplatin/irinotecan+5-FU+ leucovorin +bevacizumab (or cetuximab)
Experimental
干预措施: Irinotecan (Drug)
oxaliplatin/irinotecan+5-FU+ leucovorin +bevacizumab (or cetuximab)
Experimental
干预措施: Oxaliplatin (Drug)
结局指标
主要结局
DLTs
时间窗: 28 days after first dose
Incidence of dose limiting toxicities
ORR
时间窗: through study completion, an average of 18 months
Overall response rate
PFS
时间窗: through study completion, an average of 18 months
Progression-free survival
AE & SAE
时间窗: 30 days after the last treatment
Type, incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
MTD
时间窗: 28 days after first dose
Maximum Tolerated Dose will be determined by DLTs
次要结局
- Cmax(From first dose to end of treatment, an average of 1 year)
- Specification of anti-drug antibodies(From first dose to end of treatment, an average of 1 year)
- Ctrough(From first dose to end of treatment, an average of 1 year)
- Quantification of anti-drug antibodies(From first dose to end of treatment, an average of 1 year)
- AUC(From first dose to end of treatment, an average of 1 year)
研究者
研究点 (19)
Loading locations...
相似试验
尚未招募
2 期
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung CancerNCT07283198Jiangsu Alphamab Biopharmaceuticals Co., Ltd160
尚未招募
2 期
Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With MyelofibrosisMyelofibrosisNCT07424950United Lincolnshire Hospitals NHS Trust40
招募中
1 期
A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical CystectomyNCT07468851Jiangsu Hansoh Pharmaceutical Co., Ltd.180
尚未招募
1 期
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsNCT07279428Sichuan Baili Pharmaceutical Co., Ltd.33
招募中
2/3 期
A clinical trial to assess Safety and Immunogenicity of SII yellow fever vaccine in AdultsYellow FeverCTRI/2024/03/063471Dr Prasad Kulkarni MD580